Britain and America have signed a significant trade agreement that will guarantee zero levies on British pharmaceutical shipments entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise expenditure on drugs through the public health system. This pledge secures that import taxes on these key products will remain at nothing for a timeframe of three years.
This development follows recent threats to significantly raise import taxes on branded drug imports, with figures floated as high as double the cost.
"This agreement with the UK strengthens the worldwide climate for innovative medicines and establishes long-overdue equity to American-British drug exports," an announcement noted.
Commercial Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the United States, which is easily the primary buyer for large UK drugmakers.
Export figures reveal that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value represented 17.4% of British export trade in that period.
"This agreement secures work, increases capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Specific British Pledges
The deal entails several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
This agreement takes place against a long-running tension between the sector and the UK government over spending levels and NHS adoption.
These tensions were intensified by arguments that American consumers were charged significantly more for the identical medicines than people in the other developed nations.
Recently, several major drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
One official stated that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
